While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

A spokesperson confirmed the company plans to reduce its workforce by “less than 20%,” months after significantly lowering ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.